ReviewToxicological sciences : an official journal of the Society of Toxicology2018
Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.
Review in Toxicological sciences : an official journal of the Society of Toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Published Physiologically-based Kinetic Models and an Assessment of their Chemical Space Coverage.Alternatives to laboratory animals : ATLA · 2021Pooled it
- Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling.CPT: pharmacometrics & systems pharmacology · 2026Review
- Quantitative systems toxicology approach that integrates PBPK and core hepatic metabolism: a case study with valproic acid.Frontiers in pharmacology · 2026Article
- Assessing the Application of Physiologically Based Pharmacokinetic Models in Acute Chemical Incidents.Journal of xenobiotics · 2025Article
- The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.Pharmaceutics · 2024Review
- Article
- Pharmacokinetic Simulation and Area under the Curve Estimation of Drugs Subject to Enterohepatic Circulation.Pharmaceutics · 2024Article
- Review
- Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.Pharmaceutics · 2024Review
- Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding.EJNMMI radiopharmacy and chemistry · 2024Article
- A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim againstFrontiers in pharmacology · 2024Article
- A science-based agenda for health-protective chemical assessments and decisions: overview and consensus statement.Environmental health : a global access science source · 2023Article
- Machine Learning and Artificial Intelligence in Toxicological Sciences.Toxicological sciences : an official journal of the Society of Toxicology · 2022Review
- An Interactive Generic Physiologically Based Pharmacokinetic (igPBPK) Modeling Platform to Predict Drug Withdrawal Intervals in Cattle and Swine: A Case Study on Flunixin, Florfenicol, and Penicillin G.Toxicological sciences : an official journal of the Society of Toxicology · 2022Article
- Comparative Pharmacokinetics of Sulfadiazine and Its Metabolite N4-Acetyl Sulfadiazine in Grass Carp (Pharmaceutics · 2022Article
- Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations.CPT: pharmacometrics & systems pharmacology · 2022Article
- Predicting Nanoparticle Delivery to Tumors Using Machine Learning and Artificial Intelligence Approaches.International journal of nanomedicine · 2022Article
- High-throughput PBTK models forExpert opinion on drug metabolism & toxicology · 2021Review
- Physiological parameter values for physiologically based pharmacokinetic models in food-producing animals. Part III: Sheep and goat.Journal of veterinary pharmacology and therapeutics · 2021Review
- Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach.Pharmacological reviews · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
The development and application of physiologically based pharmacokinetic (PBPK) models in chemical toxicology have grown steadily since their emergence in the 1980s. However, critical evaluation of PBPK models to support public health decision-making across federal agencies has thus far occurred for only a few environmental chemicals. In order to encourage decision-makers to embrace the critical role of PBPK modeling in risk assessment, several important challenges require immediate attention from the modeling community. The objective of this contemporary review is to highlight 3 of these challenges, including: (1) difficulties in recruiting peer reviewers with appropriate modeling expertise and experience; (2) lack of confidence in PBPK models for which no tissue/plasma concentration data exist for model evaluation; and (3) lack of transferability across modeling platforms. Several recommendations for addressing these 3 issues are provided to initiate dialog among members of the PBPK modeling community, as these issues must be overcome for the field of PBPK modeling to advance and for PBPK models to be more routinely applied in support of public health decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.